Back to top

Aggressive Growth

Skystar Bio-Pharmaceutical announced a record-setting quarter in November, which led to sharp estimate increases.

Shares now have a Zacks #1 Rank (Strong Buy) and the dirt-cheap valuations show potential for huge returns.

Company Description

Skystar develops and makes veterinary and medical care products and is based in China. Over 170 products are spread though out 4 divisions; veterinary medicines, micro-organisms, vaccines and feed additives.

Record Revenues

Skystar announced third-quarter results on Nov 16 that showed record organic revenue of $18.5 million, which is up 45%. Margins improved slightly from 52% to 54%. The company's balance sheet is quite liquid with $41.1 million in current assets compared to just $9.1 million in current liabilities.

Earnings per share came in at 93 cents, which was about double the 47 cents the sole covering analyst was expecting. This was the company’s third consecutive earnings surprise

Outlook Jumps

While we only have 1 covering analyst that reports to Zacks, that analyst has become even more bullish on the earnings news. The estimate for the last quarter of 2010 is up 13 cents, to 57 cents.

Next year's projection is up 44 cents, to $2.25. Last year Skystar made $1.62 which means annual forecasted growth rates are 22% and 14%, respectively.

China Raises Interest Rate

Over the Christmas weekend China raised its interest rate a quarter point. While this was likely the first of many moves to tighten the monetary supply and reign in prices, the extremely cheap valuations still make Skystar attractive.

The P/E ratios are in the low single digits and the PEG is only 0.7. Given the low capitalization, under $70 million, the P/S is definitely worth noting. While trading at 1.4 times sales is not that great, it is in line with the peer group.

The Chart

You can see below that this is far from a smooth ride, but given the growth rates, valuations and potential for the region, SKBI could post some outsized returns.

Skystar Bio-Pharmaceutical - ticker SKBI >

 
<P ALIGN=

Bill Wilton is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the market-beating Zacks Small Cap Trader service

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%